October 20, 2023 – Pembrolizumab increases response in resectable gastric, gastroesophageal junction cancers
MADRID — Pembrolizumab with chemotherapy before and after surgery increased pathologic complete response among patients with locally advanced gastric or gastroesophageal junction cancer, according to findings presented at ESMO Congress.
However, the approach did not confer a statistically significant benefit in EFS or OS, results of the randomized phase 3 KEYNOTE-585 study showed.
Read more>
← October 11, 2023 – Patients with Advanced Gastric, Esophageal Cancers Maintain Quality of Life with OpdivoOctober 20, 2023 – KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma →